Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27 2023 - 9:10AM
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS),
today announced the presentation of three abstracts from its
innovative immuno-oncology pipeline at the upcoming SITC Annual
Meeting taking place November 3 - 5, 2023 at the San Diego
Convention Center in San Diego, CA.
Abstract #1351: Identifying IL-27
dependent biomarkers in lymphocytes, NK cells, and myeloid cells in
peripheral blood and the tumor microenvironmentDate and
Time: Friday, November 3, 9 a.m.–7 p.m. Pacific Daylight Time
(PDT)Location: Exhibit Halls A and B1 – San Diego Convention
Center
Abstract #468: Characteristics of
toripalimab: a next generation anti-PD-1 antibody with potent T
cell activation and enhanced clinical efficacy irrespective of
PD-L-1 statusDate and Time: Saturday, November 4, 9
a.m.–8:30 p.m. PDTLocation: Exhibit Halls A and B1 – San Diego
Convention Center
Abstract #1354: Anti-CCR8 antibody
SRF114 depletes tumor-infiltrating regulatory T cells in
dissociated tumors from patients with head and neck squamous cell
carcinomaDate and Time: Saturday, November 4, 9 a.m.–8:30
p.m. PDTLocation: Exhibit Halls A and B1 – San Diego Convention
Center
About Coherus’ Immuno-oncology
PipelineCoherus is developing an innovative
immuno-oncology pipeline that will be synergistic with its proven
commercial capabilities in oncology. Through an in-licensing
agreement with Shanghai Junshi Biosciences Ltd., Coherus is
developing toripalimab, an anti-PD-1 antibody, in the United
States and Canada. A biologics license application for
toripalimab for the treatment of nasopharyngeal carcinoma (NPC) is
under review by the FDA. Toripalimab is approved
in China for the treatment of melanoma, urothelial
cancer, esophageal squamous cell carcinoma, NPC and non-small cell
lung cancer.
Through its acquisition of Surface Oncology, Inc. earlier this
year, Coherus’ immuno-oncology pipeline now includes multiple
antibody immunotherapy candidates focused on enhancing the innate
and adaptive immune responses to enable a robust immunologic
response and enhance outcomes for patients with cancer.
Casdozokitug (formerly SRF388) is a novel, first-in-class
anti-IL-27 antibody currently being evaluated in Phase 2 clinical
trials in lung and liver cancer. CHS-114 (formerly SRF114) is a
highly selective, competitively positioned, ADCC-enhanced anti-CCR8
antibody currently in a Phase 1/2 study as a monotherapy in
patients with advanced solid tumors.
Coherus’ earlier-stage immuno-oncology pipeline targets
immune-suppressive mechanisms, including CHS-006, a TIGIT-targeted
antibody, being evaluated in a Phase 1/2 clinical trial in
combination with toripalimab in patients with advanced solid
tumors, and CHS-1000, a preclinical program targeting the novel
pathway ILT4.
About Coherus BioSciencesCoherus is a
commercial-stage biopharmaceutical company focused on the research,
development and commercialization of innovative immunotherapies to
treat cancer. Coherus’ strategy is to build a leading
immuno-oncology franchise funded with cash generated through net
sales of its diversified portfolio of FDA-approved
therapeutics.
In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody,
in the United States and Canada. The Biologics
License Application for toripalimab in combination with
chemotherapy as treatment for recurrent or metastatic
nasopharyngeal carcinoma is currently under review by the FDA.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar
of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of
Lucentis®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar of
Humira®.
Forward-Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements regarding Coherus’ ability to build
its immuno-oncology franchise to achieve a leading market position;
Coherus’ ability to generate cash and net sales; Coherus’
investment plans; Coherus’ ability to find synergies between its
I-O pipeline and its commercial operations; and expectations about
the efficacy profile of any product candidate in the future.
Such forward-looking statements involve substantial risks and
uncertainties that could cause Coherus’ actual results, performance
or achievements to differ significantly from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties inherent in the clinical
drug development process; risks related to integration of Surface’s
programs and operations; risks related to realizing the anticipated
benefits of the acquisition of Surface; risks related to Coherus’
existing and potential collaboration partners; risks of Coherus’
competitive position; the risks and uncertainties of the regulatory
approval process, including the speed of regulatory review,
international aspects of Coherus’ business and the timing of
Coherus’ regulatory filings; the risk of FDA review issues; the
risk that Coherus is unable to complete commercial transactions and
other matters that could affect the availability or commercial
potential of Coherus’ products and product candidates; and the
risks and uncertainties of possible litigation. All forward-looking
statements contained in this press release speak only as of the
date of this press release. Coherus undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the significant risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Coherus’
business in general, see Coherus’ Quarterly Report on Form 10-Q for
the fiscal quarter ended June 30, 2023 filed with
the Securities and Exchange Commission on August 2,
2023, including the section therein captioned “Risk Factors” and in
other documents Coherus files with the Securities and Exchange
Commission.
UDENYCA®, CIMERLI® and YUSIMRY™, whether or not appearing
in large print or with the trademark symbol, are trademarks of
Coherus, its affiliates, related companies or its licensors or
joint venture partners unless otherwise noted. Trademarks and trade
names of other companies appearing in this press release are, to
the knowledge of Coherus, the property of their respective
owners.
Coherus Contact Information:For Investors &
Media:Jodi Sievers, VP, Corporate CommunicationsIR@coherus.com
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jul 2023 to Jul 2024